ISG15 and lung carcinoma: Consistent with the above findings, we found that for breast cancer, lung cancer, pancreatic cancer, AML, and myeloma, the expression levels of ISG15 markedly influence patients’ OS (breast cancer: OS, HR = 1.4, log-rank P = 0.0021; lung cancer: OS, HR = 1.46, log-rank P = 2.5e−07; pancreatic cancer: OS, HR = 1.26, log-rank P = 0.0023; AML: OS, HR = 1.22, log-rank P = 0.0019; myeloma: OS, HR = 1.6, log-rank P = 1.3e−06).